Browse
Submit Data
Databases
API
Help

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression profile of the endocrine therapy sensitive breast cancer cells MCF7 depleted of PBX1

ABSTRACT: Effect of PBX1 silencing on global gene expression of MCF7 cells stimulated with EGF. The hypothesis tested was that PBX1 is essential for EGF signaling in ERa positive breast cancer cells. Total RNA was obtained from MCF7 cells treated with siRNA directed at PBX1 or an siControl for 72h. Cells were then stimulated with estradiol (EGF) for 3h prior to RNA extraction.

ORGANISM(S): Homo sapiens

SUBMITTER: Magnani L

PROVIDER: S-ECPF-GEOD-39417 | biostudies-other | 2013 Apr

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Expression profile of the endocrine therapy sensitive breast cancer cells MCF7 depleted of PBX1

2013-05-01 | GSE39417 | GEO

Expression profile of the endocrine therapy sensitive breast cancer cells MCF7 depleted of PBX1

Project description:Effect of PBX1 silencing on global gene expression of MCF7 cells stimulated with EGF. The hypothesis tested was that PBX1 is essential for EGF signaling in ERa positive breast cancer cells. Total RNA was obtained from MCF7 cells treated with siRNA directed at PBX1 or an siControl for 72h. Cells were then stimulated with estradiol (EGF) for 3h prior to RNA extraction.

2013-05-01 | E-GEOD-39417 | biostudies-arrayexpress

Expression profile of the endocrine therapy resistant breast cancer cells LTED depleted of PBX1 or treated with the gamma-secretase inhibitor MRK003

Project description: Not available

| S-ECPF-GEOD-36928 | biostudies-other

Expression profile of the endocrine therapy resistant breast cancer cells LTED depleted of PBX1 or treated with the gamma-secretase inhibitor MRK003

Project description:Analysis of the response to PBX1 deprivation either using an siRNA approach or using a chemicalcompound indirectly targeting it. Deprivation of PBX1 is hypothesized to be essential for the growth of endocrine therapy resistant breast cancer cells (LTED) Total RNA was obtained from cells treated with siPBX1 or a control siRNA. The second set contains RNA from cells treated with MRK003 or a control (DMSO).

2013-05-01 | E-GEOD-36928 | biostudies-arrayexpress

Expression profile of the endocrine therapy resistant breast cancer cells LTED depleted of PBX1 or treated with the gamma-secretase inhibitor MRK003

2013-05-01 | GSE36928 | GEO

Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.

Project description: Not available

| S-EPMC4095694 | biostudies-literature

Phosphoproteomics measurement of clonal endocrine therapy sensitive and resistant breast cancer populations

Project description:Around two thirds of breast tumors are characterized by the expression of estrogen receptor α and are therapeutically treated by blocking estrogen signaling. First line endocrine therapeutics are Tamoxifen which displaces estrogen form its receptor preventing receptor activation and aromatase inhibitors which prevent the formation of estrogen and thereby hormone-deprive the tumors. Therapy resistance remains a major clinical problem, especially for patients with late-stage diagnoses. Tumor heterogeneity may promote therapy resistance either through the selection of pre-existing rare clones or by providing a repertoire of cells that may develop resistance over time. In order to study endocrine therapy resistance on a clonal level, we have developed barcoded (allowing the tracking of single cells) endocrine therapy sensitive and resistant breast cancer cell lines. From these complex cell pools, multiple single cells characterized by a specific barcode were isolated and grown out. We then subjected the clones to phosphoproteomics measurement by Mass spectrometry. Based on their phosphorylation pattern, the kinase activity profiles of endocrine therapy resistant clones were determined to identify differentially activated kinases with implications in therapy resistance.

2024-01-26 | PXD040478 | Pride

Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines.

Project description: Not available

| S-EPMC3445463 | biostudies-literature

MicroRNA expression profiling of endocrine sensitive and resistant breast cancer cell lines.

Project description: Not available

| S-EPMC9307586 | biostudies-literature

Metastatic breast cancer: Endocrine therapy landscape reshaped.

Project description: Not available

| S-EPMC5655644 | biostudies-literature